Lung Cancer | Specialty

FDA Grants Brigatinib Priority Review for ALK-Positive NSCLC

October 31st 2016

The FDA has has granted a priority review to a new drug application for brigatinib for patients with metastatic ALK-positive non–small cell lung cancer who are resistant to prior crizotinib.

Expert Discusses Stem Cell Research and Personalizing Lung Cancer Care

October 30th 2016

Nivolumab Combos Explored in First-Line NSCLC Trial

October 28th 2016

Although nivolumab has demonstrated a clear survival advantage compared with chemotherapy in patients with progressive non–small cell lung cancer who express PD-L1 in their tumor cells, the same cannot be said for those who are PD-L1–negative.

Dr. Neal on Immunotherapy Combinations in Lung Cancer

October 27th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses what immunotherapy combinations oncologists are currently using in the treatment of patients with lung cancer.

Dr. Velcheti on Potential of Alectinib in Frontline ALK-Positive NSCLC

October 26th 2016

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.

Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC

October 26th 2016

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).

TP53 Mutations Loom Large in Lung Cancer Study

October 25th 2016

Although there are no drugs that target TP53 mutations in any tumor type, a recent analysis of a non–small cell lung cancer sample set raises the prospect that a more detailed understanding of this aberration eventually could help direct therapy.

Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC

October 25th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

FDA Approves Pembrolizumab for Frontline PD-L1+ NSCLC

October 25th 2016

The FDA has approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic non­–small cell lung cancer whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

October 25th 2016

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

October 24th 2016

Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.

Dr. Patrick M. Forde on Neoadjuvant Nivolumab in NSCLC

October 20th 2016

Patrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses a study presented at ESMO 2016 on neoadjuvant nivolumab, in early stage resectable non-small-cell lung cancer (NSCLC).

Dr. Rimm on Biomarker Testing in Lung Cancer

October 19th 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses various options for biomarker testing in lung cancer.

FDA Approves Atezolizumab for Lung Cancer

October 19th 2016

The FDA has approved atezolizumab (Tecentriq) for the treatment of patients with metastatic non–small cell lung cancer who have progressed after a platinum-containing regimen and an FDA-approved targeted therapy for those patients harboring EGFR or ALK abnormalities.

Sangeetha Palakurthi on FDA Approval of Atezolizumab in NSCLC

October 19th 2016

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses the FDA approval of atezolizumab (Tecentriq) for the treatment of patients with non–small cell lung cancer (NSCLC).

Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLC

October 18th 2016

Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.

Custirsen Combo Misses OS Goal in Phase III NSCLC Trial

October 16th 2016

The combination of custirsen with docetaxel failed to significantly extend overall survival compared with docetaxel alone as a second-line treatment for patients with non–small cell lung cancer.

Dr. Sabari on Immunotherapy Updates in Small Cell Lung Cancer

October 14th 2016

Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses recent findings in immunotherapy as potential treatment for patients with small cell lung cancer.

Dr. Herbst on Advances of Immunotherapy in Lung Cancer

October 14th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the current and future impact of immunotherapy in lung cancer.

ALK+ NSCLC Landscape Shifting With Emerging Agents

October 12th 2016

Ranee Mehra, MD, provides an overview of ALK inhibition in non–small cell lung cancer, an observation of the most common treatment-related adverse events, and what impact in-development agents will likely have on the expanding field.